Larimar Therapeutics (LRMR) Cash from Investing Activities (2016 - 2020)
Historic Cash from Investing Activities for Larimar Therapeutics (LRMR) over the last 8 years, with Q4 2020 value amounting to -$23.5 million.
- Larimar Therapeutics' Cash from Investing Activities fell 4699000.0% to -$23.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was $17.1 million, marking a year-over-year increase of 2069036.14%. This contributed to the annual value of -$85.4 million for FY2024, which is 35601.0% down from last year.
- Per Larimar Therapeutics' latest filing, its Cash from Investing Activities stood at -$23.5 million for Q4 2020, which was down 4699000.0% from -$8000.0 recorded in Q3 2020.
- Larimar Therapeutics' 5-year Cash from Investing Activities high stood at $41.4 million for Q2 2020, and its period low was -$47.4 million during Q3 2018.
- For the 5-year period, Larimar Therapeutics' Cash from Investing Activities averaged around $5.1 million, with its median value being $8.3 million (2018).
- The largest annual percentage gain for Larimar Therapeutics' Cash from Investing Activities in the last 5 years was 503107.14% (2020), contrasted with its biggest fall of 4699000.0% (2020).
- Over the past 5 years, Larimar Therapeutics' Cash from Investing Activities (Quarter) stood at $16.9 million in 2016, then fell by 24.97% to $12.7 million in 2017, then rose by 12.43% to $14.3 million in 2018, then crashed by 100.35% to -$50000.0 in 2019, then tumbled by 46990.0% to -$23.5 million in 2020.
- Its Cash from Investing Activities was -$23.5 million in Q4 2020, compared to -$8000.0 in Q3 2020 and $41.4 million in Q2 2020.